ArticleOncology letters2026
Tanshinone IIA targets RNF123 to inhibit non-small cell lung cancer cell proliferation, migration and invasion via KAT2B-mediated H3K18ac modification.
Article in Oncology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tanshinone IIA (TSIIA) exerts antitumor effects. The present study aimed to explore the pharmacological effect of TSIIA on lung cancer development and assess the potential underlying mechanism of action. Cell viability and proliferation were assessed using Cell Counting Kit-8 and 5-ethynyl-20-deoxyuridine assays, respectively. Transwell assays were performed to determine cell migration and invasion. Histone H3 lysine 18 acetylation (H3K18ac) and histone H4 lysine 8 acetylation (H4K8ac) enrichment in the RING finger protein 123 (RNF123) promoter and the interaction between lysine acetyltransferase 2B (KAT2B) and the RNF123 promoter were analyzed by chromatin immunoprecipitation assays. The results indicated that RNF123 was weakly expressed in lung cancer cells, and its upregulation decreased lung cancer cell viability, proliferation, migration, invasion and epithelial-mesenchymal transition. Sodium TSIIA sulfate (STS) treatment inhibited the non-small cell lung cancer (NSCLC) cell malignant phenotypes, which were reversed by the knockdown of RNF123. Mechanistically, TSIIA promoted KAT2B-mediated H3K18ac modification at the promoter region of the RNF123 gene, leading to upregulated RNF123 expression in NSCLC cells. Additionally, KAT2B knockdown prevented the STS-induced inhibition of NSCLC cell malignant phenotypes. Furthermore, RNF123 upregulation restored the effect of KAT2B knockdown on STS-treated NSCLC phenotypes. In conclusion, TSIIA inhibited the NSCLC cell malignant phenotypes via the epigenetic modification of RNF123.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.